Skip to content

Genomics of Chronic Renal Allograft Rejection (The GoCAR Study)

Genomics of Chronic Renal Allograft Rejection

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00611702
Enrollment
588
Registered
2008-02-11
Start date
2008-06-30
Completion date
2013-07-31
Last updated
2015-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplantation

Keywords

ELISPOT, RT-PCR, Luminex, Genomics

Brief summary

Doctors have had success preventing certain types of kidney transplant rejection by suppressing the immune system. However, an individual's genetic make-up and the strength of an immune response to a transplant may also determine whether a transplanted organ is rejected. The purpose of this study is to look at the genetic profile and immune response of people who have had kidney transplants and to correlate the findings with kidney transplant rejection episodes. Donor genetic profiles will also be studied and correlated with the recipient's information.

Detailed description

New immunosuppressive drugs have improved short-term transplant survival but have not affected long-term transplant survival. Rejection is caused by both immunological and non-immunological factors from both the donor and the recipient. Although the exact cause of chronic rejection is not known, it is associated with the presence of C4d, a degradation product of the antibody response cascade, and the presence of circulating donor-specific antibodies (DSAs). The purpose of this study is to determine the role of cell- and antibody-mediated responses in chronic rejection of transplants, to determine the gene expression profile associated with the development of chronic rejection, and to determine whether variants of specific genes cause susceptibility to rejection. This is an observational study of people who will be receiving kidney transplants and participants will be followed for 2 years. Study visits for kidney transplant recipients will occur at study entry and at months 3, 6, 12, 18, and 24 after transplant. At these visits, adverse event assessment, rejection assessment, medication history questionnaire, and blood collection will occur. At some visits, a physical exam and a kidney biopsy will occur. Blood will also be collected from living kidney donors at the time of donation if both donor and recipient agree to be in the study. This study will be take place at 4 clinical sites: Mount Sinai School of Medicine, University of Wisconsin-Madison, Westmead Hospital, and Northwestern Memorial Hospital. Brigham and Women's Hospital and Massachusetts General Hospital will also participate in the study as central laboratories.

Interventions

PROCEDUREKidney biopsy

Kidney biopsy (recipients only) will be obtained for RT-PCR, microarray analyses and histology.

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
Lead SponsorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Kidney transplant candidates from living or deceased donors * Male or female, ages 18-75 years * Subject must be able to understand and provide written informed consent * Living Donors - Recipient also consents to participate in the study

Exclusion criteria

* Presence of Donor Specific Antibodies in living donor recipients prior to transplantation OR positive cross match according to site-specific technique in cadaveric donor recipients * Recipients of multiple organ transplants, with the exception of kidney/pancreas transplants. * Inability or unwillingness to comply with the study protocol.

Design outcomes

Primary

MeasureTime frame
Correlation of chronic rejection with patterns and intensity of recipient alloreactivityThroughout study
Correlation of chronic rejection with recipient gene expression profilesThroughout study
Correlation of chronic rejection with polymorphic variants of specific susceptibility genes in donor and recipientThroughout study

Secondary

MeasureTime frame
Correlation of the development of donor-specific antibodies after transplant and/or the presence of C4d staining of peritubular basement membranes on renal biopsy with chronic rejectionThroughout study
Correlation of the development of donor specific antibodies after transplant and/or the presence of C4d staining with patterns and intensity of recipient alloreactivityThroughout study
Correlation of the development of donor-specific antibodies after transplant and/or the presence of C4d staining of peritubular basement membranes on renal biopsy allograft dysfunction as defined by the protocolThroughout study
Correlation of the development of donor specific antibodies after transplant and/or the presence of C4d staining with recipient gene expression profilesThroughout study
Correlation of the development of donor-specific antibodies after transplant and/or the presence of C4d staining of peritubular basement membranes on renal biopsy with polymorphic variants of specific susceptibility genes in donor and recipientThroughout study

Countries

Australia, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026